|The following article is part of conference coverage from Kidney Week 2018 in San Diego hosted by the American Society of Nephrology. Renal & Urology News staff will be reporting live on medical studies conducted by nephrologists and other specialists who are tops in their field in acute kidney injury, chronic kidney disease, dialysis, transplantation, and more. Check back for the latest news from Kidney Week 2018.|
SAN DIEGO—Gout is much more common among solid organ transplant (SOT) recipients than in the general US population, study findings presented at the American Society of Nephrology’s Kidney Week 2018 conference suggest.
Using Medicare and commercial claims databases, Mark D. Brigham, PhD, of Trinity Partners LLC in Waltham, Massachusetts, and colleagues found that the prevalence of active gout was 11.3% among SOT recipients (40,400 of 356,000 recipients) compared with 1.1% of the general US population (3,420,000 of 323,100,000 individuals), based on 2016 claims data.
The prevalence was highest among kidney and heart transplant recipients (13.1% and 12.7%, respectively). Liver and lung transplant recipients had a prevalence of 6.7% and 5.6%, respectively, the investigators reported in a poster presentation.
Of the SOT recipients with active gout, 73% received gout treatment and 27% did not.
The investigators defined active gout as at least 1 claim with any gout diagnosis code in 2016.
“In light of previously published evidence that gout is an independent risk factor for serious poor health outcomes, these findings suggest that gout should be considered a serious concern in the ongoing care of the large and growing prevalent SOT population,” the authors concluded.
|Visit Renal & Urology News’ conference section for continuous coverage from Kidney Week 2018.|
Brigham MD, Li JW, Milgroom A, et al. Prevalence of gout in the surviving US solid organ transplantation population. Presented at the American Society of Nephrology’s Kidney Week 2018 conference in San Diego, Oct. 23-28. Poster TH-PO158.